ConductScience.org, home

Paper22012269

Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.

Van Regenmortel MH. Arch Virol, 2012. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Papers, record 22012269. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22012269

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.
PubMed
Journal
Arch Virol
PubMed
Year
2012
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2021-10-20
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Van Regenmortel MHMarc H V

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AIDS VaccinesMajor topic
Antigens, ViralMajor topic
Drug DesignMajor topic
HIV InfectionsMajor topic
HIV-1Major topic
Animals
Epitopes
Humans

Source PubMed

Download CSV of topics

References207

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12427937Comparison of different methods for localizing antigenic regions in histone H2A.Mol Immunol1986https://conductscience.org/library/papers/2427937PubMed
215795308Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.J Virol2005https://conductscience.org/library/papers/15795308PubMed
317418361Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.Virology2007https://conductscience.org/library/papers/17418361PubMed
47973652Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.Science1994https://conductscience.org/library/papers/7973652PubMed
519552398HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.Biochemistry2009https://conductscience.org/library/papers/19552398PubMed
61993848Binding to native proteins by antipeptide monoclonal antibodies.J Immunol1991https://conductscience.org/library/papers/1993848PubMed
717409160Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.J Virol2007https://conductscience.org/library/papers/17409160PubMed
811698650Degeneracy and complexity in biological systems.Proc Natl Acad Sci U S A2001https://conductscience.org/library/papers/11698650PubMed
92441250Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodies.Mol Immunol1987https://conductscience.org/library/papers/2441250PubMed
1015036900From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology.Mol Immunol2004https://conductscience.org/library/papers/15036900PubMed
112416848Theoretical considerations of the ability of monoclonal antibodies to detect antigenic differences between closely related variants, with particular reference to heterospecific reactions.J Immunol Methods1985https://conductscience.org/library/papers/2416848PubMed
127692082A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.J Virol1993https://conductscience.org/library/papers/7692082PubMed
1312089434Diversity considerations in HIV-1 vaccine selection.Science2002https://conductscience.org/library/papers/12089434PubMed
1421233310A therapeutic dendritic cell-based vaccine for HIV-1 infection.J Infect Dis2011https://conductscience.org/library/papers/21233310PubMed
1515607824Degeneracy, mimicry and crossreactivity in immune recognition.Mol Immunol2005https://conductscience.org/library/papers/15607824PubMed
1610368281Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.Structure1999https://conductscience.org/library/papers/10368281PubMed
1712447900Reductionism and the search for structure-function relationships in antibody molecules.J Mol Recognit2002https://conductscience.org/library/papers/12447900PubMed
187941328Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.Virology1994https://conductscience.org/library/papers/7941328PubMed
1913789973Immunological speculations.Annu Rev Microbiol1960https://conductscience.org/library/papers/13789973PubMed
2015247456Outstanding questions on HIV vaccine trial.Science2004https://conductscience.org/library/papers/15247456PubMed

See all 207 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
33780441Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification.PLoS Comput Biol2021https://conductscience.org/library/papers/33780441PubMed
31921119Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria.Front Immunol2019https://conductscience.org/library/papers/31921119PubMed
29546103Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?AIMS Public Health2015https://conductscience.org/library/papers/29546103PubMed
29387066Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.Front Immunol2017https://conductscience.org/library/papers/29387066PubMed
28944092
MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA.
J Vaccines Vaccin2017https://conductscience.org/library/papers/28944092PubMed
27657055Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.Int J Mol Sci2016https://conductscience.org/library/papers/27657055PubMed
27458032Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking.Front Immunol2016https://conductscience.org/library/papers/27458032PubMed
26344344Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.Vaccines (Basel)2013https://conductscience.org/library/papers/26344344PubMed
26157442Editorial: Paradigm Changes are Required in HIV Vaccine Research.Front Immunol2015https://conductscience.org/library/papers/26157442PubMed
25477882
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.
Front Immunol2014https://conductscience.org/library/papers/25477882PubMed
25210191Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.J Virol2014https://conductscience.org/library/papers/25210191PubMed
24033298Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.Curr HIV Res2013https://conductscience.org/library/papers/24033298PubMed
23866844Development of prophylactic vaccines against HIV-1.Retrovirology2013https://conductscience.org/library/papers/23866844PubMed
23227445Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.J AIDS Clin Res2012https://conductscience.org/library/papers/23227445PubMed
23089396Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.J Immunol2012https://conductscience.org/library/papers/23089396PubMed
22912636Controlling the HIV/AIDS epidemic: current status and global challenges.Front Immunol2012https://conductscience.org/library/papers/22912636PubMed
22787464Basic research in HIV vaccinology is hampered by reductionist thinking.Front Immunol2012https://conductscience.org/library/papers/22787464PubMed
22546090
Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies.
BMC Res Notes2012https://conductscience.org/library/papers/22546090PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22012269

GET https://conductscience.org/api/papers/v1/22012269/references?page=2